Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
August 05, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Changes to Board of Directors
July 02, 2020 07:30 ET
|
Harpoon Therapeutics
Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs. Luke Evnin and Patrick Baeuerle step down from the Harpoon board Dr. Baeuerle remains as...
Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences
June 17, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
June 11, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 06, 2020 16:05 ET
|
Harpoon Therapeutics
Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at...
Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference
November 26, 2019 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 06, 2019 16:05 ET
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian...
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 05, 2019 16:05 ET
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerInitiated Phase 1/2a clinical trial for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
July 31, 2019 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 08:30 ET
|
Harpoon Therapeutics
Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerNet proceeds of approximately $71 million from completion...